FDA Approves INBRIJA — Merz Pharmaceuticals, LLC

# FDA Approves Merz Pharmaceuticals' INBRIJA (Levodopa Inhalation Powder) for Parkinson's Disease Merz Pharmaceuticals has received FDA approval for INBRIJA, a novel inhaled formulation of levodopa designed to provide rapid symptom relief during 'off' episodes in Parkinson's disease patients, marking the first and only inhalation-based dopaminergic therapy and positioning the company to capture market share in the estimated $3+ billion Parkinson's treatment space. The innovative respiratory delivery mechanism offers a potential competitive advantage over existing